Recombinant Human SCEL, N-His

Description of Recombinant Human SCEL, N-His

Introduction to Recombinant Human SCEL, N-His

Recombinant Human SCEL, N-His is a protein that has garnered significant attention in the field of drug discovery and development. This protein, also known as Secretory Carrier Membrane Protein-like (SCEL), is a member of the Secretory Carrier Membrane Protein (SCAMP) family. It is primarily found in secretory vesicles of various tissues, including the pancreas, liver, and lung. Recombinant Human SCEL, N-His has shown to have important roles in cellular processes such as vesicle trafficking and exocytosis. In this article, we will delve into the structure, activity, and potential applications of this protein as a drug target.

Structure of Recombinant Human SCEL, N-His

Recombinant Human SCEL, N-His is a transmembrane protein that consists of 247 amino acids. It has a molecular weight of approximately 28 kDa. The protein is composed of a cytoplasmic N-terminus, a transmembrane domain, and a luminal C-terminus. The transmembrane domain is composed of hydrophobic amino acids that allow the protein to span the membrane and interact with other proteins and lipids. The luminal C-terminus contains a conserved cysteine-rich domain, which is essential for the protein’s function in vesicle trafficking.

Activity of this protein

Recombinant Human SCEL, N-His has been shown to play a crucial role in the regulation of vesicle trafficking and exocytosis. It acts as a scaffolding protein that interacts with other proteins involved in these processes, such as SNARE proteins and the exocyst complex. This interaction is essential for the targeting and fusion of secretory vesicles to the plasma membrane, allowing for the release of their contents into the extracellular space. Additionally, studies have shown that Recombinant Human SCEL, N-His is involved in the regulation of insulin secretion in pancreatic beta cells, making it a potential target for diabetes treatment.

Potential Applications of Recombinant Human SCEL, N-His as a Drug Target

Given its crucial role in vesicle trafficking and exocytosis, Recombinant Human SCEL, N-His has emerged as a promising drug target. Disruption of these processes has been linked to various diseases, including diabetes, neurodegenerative disorders, and cancer. Therefore, targeting Recombinant Human SCEL, N-His could have significant therapeutic implications.

One potential application of Recombinant Human SCEL, N-His as a drug target is in the treatment of diabetes. As mentioned earlier, this protein plays a role in regulating insulin secretion in pancreatic beta cells. Therefore, targeting Recombinant Human SCEL, N-His could potentially improve insulin secretion and glucose control in diabetic patients.

Another potential application is in the treatment of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Dysfunction in vesicle trafficking and exocytosis has been implicated in these diseases, and targeting Recombinant Human SCEL, N-His could help restore these processes and potentially slow down the progression of these disorders.

Additionally, Recombinant Human SCEL, N-His has also been identified as a potential target for cancer treatment. Aberrant exocytosis has been observed in cancer cells, and targeting Recombinant Human SCEL, N-His could potentially disrupt this process and inhibit tumor growth.

Conclusion

In conclusion, Recombinant Human SCEL, N-His is a transmembrane protein that plays a crucial role in vesicle trafficking and exocytosis. Its involvement in various cellular processes and its potential as a drug target make it an attractive candidate for further research and development.